{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:37:43Z","timestamp":1792719463148,"version":"4.5.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1053\/j.seminoncol.2014.07.004","type":"journal-article","created":{"date-parts":[[2014,7,22]],"date-time":"2014-07-22T14:31:32Z","timestamp":1406039492000},"page":"613-622","source":"Crossref","is-referenced-by-count":64,"title":["Radioimmunoconjugates for the Treatment of Cancer"],"prefix":"10.1053","volume":"41","author":[{"given":"Fran\u00e7oise","family":"Kraeber-Bod\u00e9r\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bodet-Milin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Rousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Eug\u00e8ne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Pallardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Frampas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Ferrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Gaschet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Davodeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Gestin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Faivre-Chauvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Barbet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ch\u00e9rel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminoncol.2014.07.004_bib1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/978-1-61779-974-7_38","article-title":"Radiolabeled antibodies for cancer imaging and therapy","volume":"907","author":"Barbet","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib2","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrclinonc.2011.160","article-title":"Clinical radioimmunotherapy--the role of radiobiology","volume":"8","author":"Pouget","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib3","doi-asserted-by":"crossref","first-page":"6763","DOI":"10.1200\/JCO.2005.18.622","article-title":"Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results","volume":"23","author":"Liersch","year":"2005","journal-title":"J Clin Onco"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib4","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/cncr.24795","article-title":"Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer","volume":"116","author":"Tagawa","year":"2010","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib5","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.2005.03.8471","article-title":"Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy","volume":"24","author":"Goldenberg","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib6","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1200\/JCO.2005.04.4917","article-title":"Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group","volume":"24","author":"Chatal","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib7","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/bjc.2013.376","article-title":"Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results","volume":"109","author":"Schoffelen","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib8","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1002\/cncr.27592","article-title":"Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: a phase 1 trial","volume":"118","author":"Ocean","year":"2012","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1053\/j.seminoncol.2014.07.004_bib9","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.4103\/0973-1482.55139","article-title":"Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors","volume":"5","author":"Chatal","year":"2009","journal-title":"J Cancer Res Ther"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib10","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","article-title":"Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan","volume":"22","author":"Witzig","year":"2007","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib11","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","article-title":"Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin\u2019s lymphomas","volume":"23","author":"Fisher","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib12","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2006.09.2882","article-title":"Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy","volume":"25","author":"Czuczman","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib13","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.2967\/jnumed.111.089920","article-title":"Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the International Radioimmunotherapy Network","volume":"52","author":"Hohloch","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib14","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1002\/cncr.27418","article-title":"A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma","volume":"118","author":"Shimoni","year":"2012","journal-title":"Cancer"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib15","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1200\/JCO.2012.45.9453","volume":"31","author":"Vose","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib16","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","article-title":"Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma","volume":"26","author":"Morschhauser","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib17","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1200\/JCO.2012.45.6400","article-title":"90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III First-line indolent trial","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib18","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-10-0162","article-title":"Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients","volume":"16","author":"Zinzani","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib19","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2012.42.2444","article-title":"Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499","volume":"30","author":"Smith","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib20","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2012.42.4101","article-title":"Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016","volume":"31","author":"Press","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib21","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2011.41.1553","article-title":"90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial","volume":"31","author":"Scholz","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1200\/JCO.2013.50.3110","article-title":"Fractionated 90Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase ii study in patients requiring treatment according to GELF\/BNLI criteria","volume":"32","author":"Illidge","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib23","first-page":"2000","article-title":"Radioimmunotherapy of non-Hodgkin\u2019s lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?","volume":"44","author":"Sharkey","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib24","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1200\/JCO.2009.27.7863","article-title":"High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I\/II study in non-Hodgkin\u2019s lymphoma","volume":"28","author":"Morschhauser","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib25","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1182\/blood-2008-11-188896","article-title":"A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody\/radioantibody therapy","volume":"113","author":"Sharkey","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib26","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1158\/1078-0432.CCR-08-0404","article-title":"Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab)","volume":"14","author":"Mattes","year":"2008","journal-title":"Clin. Cancer Res"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib27","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/ejh.12183","article-title":"BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle","volume":"91","author":"Chevallier","year":"2013","journal-title":"Eur J Haematol"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2967\/jnumed.108.058651","article-title":"MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy","volume":"51","author":"Sgouros","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib29","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2012-11-467035","article-title":"Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model","volume":"121","author":"Orozco","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib30","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s13277-012-0362-y","article-title":"Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients","volume":"33","author":"Rousseau","year":"2012","journal-title":"Tumour Biol"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib31","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.2967\/jnumed.112.111997","article-title":"213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma","volume":"54","author":"Ch\u00e9rel","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib32","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1182\/blood.V100.4.1233.h81602001233_1233_1239","article-title":"Targeted alpha particle immunotherapy for myeloid leukemia","volume":"100","author":"Jurcic","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib33","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1200\/JCO.2005.05.160","article-title":"Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer","volume":"23","author":"Bander","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib34","first-page":"3190s","article-title":"Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I\/II clinical trial","volume":"5","author":"Kraeber-Bod\u00e9r\u00e9","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib35","first-page":"247","article-title":"Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial","volume":"47","author":"Kraeber-Bod\u00e9r\u00e9","year":"2006","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib36","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2967\/jnumed.111.101865","article-title":"Phase II trial of anticarcinoembryonic antigen pretargeted radioimmunotherapy in progressive metastatic medullary thyroid carcinoma: biomarker response and survival improvement","volume":"53","author":"Salaun","year":"2012","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib37","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2967\/jnumed.107.046185","article-title":"Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting","volume":"49","author":"Goldenberg","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib38","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.semnuclmed.2009.12.002","article-title":"Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy","volume":"40","author":"Sharkey","year":"2010","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib39","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1200\/JCO.2012.42.4887","article-title":"Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology","volume":"30","author":"Knowles","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib40","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2967\/jnumed.111.089771","article-title":"Immuno-PET of cancer: a revival of antibody imaging","volume":"52","author":"Boerman","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib41","first-page":"20","article-title":"Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A preclinical study on MDA-MB-468 xenograft tumors","volume":"1","author":"Rousseau","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging Res"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib42","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2967\/jnumed.110.075648","article-title":"ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model","volume":"51","author":"Heskamp","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib43","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2967\/jnumed.110.086165","article-title":"(124)I-huA33 antibody PET of colorectal cancer","volume":"52","author":"Carrasquillo","year":"2011","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib44","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00259-006-0160-0","article-title":"Preparation and evaluation of (89)Zr-Zevalin for monitoring of (90)Y-Zevalin biodistribution with positron emission tomography","volume":"33","author":"Perk","year":"2006","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib45","doi-asserted-by":"crossref","first-page":"892","DOI":"10.2967\/jnumed.109.073239","article-title":"Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules","volume":"51","author":"Baum","year":"2010","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib46","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/clpt.2010.12","article-title":"Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer","volume":"87","author":"Dijkers","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib47","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.2967\/jnumed.112.118612","article-title":"64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer","volume":"54","author":"Tamura","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib48","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/1535-7163.MCT-09-0862","article-title":"Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts","volume":"9","author":"Schoffelen","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1053\/j.seminoncol.2014.07.004_bib49","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00259-013-2434-7","article-title":"Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody","volume":"40","author":"van Rij","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775414001730?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775414001730?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T13:27:37Z","timestamp":1598102857000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775414001730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0093775414001730"],"URL":"https:\/\/doi.org\/10.1053\/j.seminoncol.2014.07.004","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]}}}